Jefferies & Co Downgrades Albany Molecular (AMRI) to Hold
More News related to AMRI
- AMRI Initiates Phase I Study on ALB109564
- AMRI Initiates Phase I Study of Proprietary Oncology Drug Candidate
- AMRI CEO Adopts Rule 10B5-1 Stock Trading Plan
- Unusual 11 Mid-Day Movers 8/6: VRNM, CBOU, SCA, AMRI Higher; INAP, ENTR, MFLX, ABCO Lower
- Pre-Open Movers 8/6: Freddie Mac (FRE) Sinks On Results, Isolagen (ILE) Surges On Drug Results
More News related to Downgrades
- Raymond James Downgrades Williams-Sonoma (WSM) to Market Perform
- Raymond James Downgrades FPIC Insurance (FPIC) to Market Perform
- Bernstein Downgrades Novo Nordisk (NVO) to Underperform
- Robert Baird Downgrades S.Y. Bancorp (SYBT) to Neutral
- Matrix USA Rating Changes 8/29
Jefferies & Co downgrades Albany Molecular (Nasdaq: AMRI) from Buy to Hold. Price target $15.50.
Albany Molecular Research, Inc. provides scientific services, technologies and products.
Related Categories
DowngradesStocks Mentioned
-0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
